Premium
Can creatine supplementation form carcinogenic heterocyclic amines in humans?
Author(s) -
Pereira Renato Tavares dos Santos,
Dörr Felipe Augusto,
Pinto Ernani,
Solis Marina Yazigi,
Artioli Guilherme Giannini,
Fernandes Alan Lins,
Murai Igor Hisashi,
Dantas Wagner Silva,
Seguro Antônio Carlos,
Santinho Mirela Aparecida Rodrigues,
Roschel Hamilton,
Carpentier Alain,
Poortmans Jacques Remi,
Gualano Bruno
Publication year - 2015
Publication title -
the journal of physiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.802
H-Index - 240
eISSN - 1469-7793
pISSN - 0022-3751
DOI - 10.1113/jp270861
Subject(s) - creatine , carcinogen , creatinine , quinoxaline , chemistry , medicine , placebo , cancer , crossover study , endocrinology , creatine monohydrate , biochemistry , pathology , organic chemistry , alternative medicine
Key points There is a long‐standing concern that creatine supplementation could be associated with cancer, possibly by facilitating the formation of carcinogenic heterocyclic amines (HCAs). This study provides compelling evidence that both low and high doses of creatine supplementation, given either acutely or chronically, does not cause a significant increase in HCA formation. HCAs detection was unrelated to creatine supplementation. Diet was likely to be the main factor responsible for HCAs formation after either placebo ( n = 6) or creatine supplementation ( n = 3). These results directly challenge the recently suggested biological plausibility for the association between creatine use and risk of testicular germ cell cancer.Abstract Creatine supplementation has been associated with increased cancer risk. In fact, there is evidence indicating that creatine and/or creatinine are important precursors of carcinogenic heterocyclic amines (HCAs). The present study aimed to investigate the acute and chronic effects of low‐ and high‐dose creatine supplementation on the production of HCAs in healthy humans (i.e. 2‐amino‐1‐methyl‐6‐phenylimidazo[4,5‐ b ]pyridine (PhIP), 2‐amino‐3,8‐dimethylimidazo[4,5‐ f ]quinoxaline (8‐MeIQx), 2‐amino‐(1,6‐dimethylfuro[3,2‐e]imidazo[4,5‐b])pyridine (IFP) and 2‐amino‐3,4,8‐trimethylimidazo[4,5‐ f ]quinoxaline (4,8‐DiMeIQx)). This was a non‐counterbalanced single‐blind crossover study divided into two phases, in which low‐ and high‐dose creatine protocols were tested. After acute (1 day) and chronic supplementation (30 days), the HCAs PhIP, 8‐MeIQx, IFP and 4,8‐DiMeIQx were assessed through a newly developed HPLC–MS/MS method. Dietary HCA intake and blood and urinary creatinine were also evaluated. Out of 576 assessments performed (from 149 urine samples), only nine (3 from creatine and 6 from placebo) showed quantifiable levels of HCAs (8‐MeIQx: n = 3; 4,8‐DiMeIQx: n = 2; PhIP: n = 4). Individual analyses revealed that diet rather than creatine supplementation was the main responsible factor for HCA formation in these cases. This study provides compelling evidence that both low and high doses of creatine supplementation, given either acutely or chronically, did not cause increases in the carcinogenic HCAs PhIP, 8‐MeIQx, IFP and 4,8‐DiMeIQx in healthy subjects. These findings challenge the long‐existing notion that creatine supplementation could potentially increase the risk of cancer by stimulating the formation of these mutagens.